In addition to your spreadsheet, you will need to provide answers to the following questions: 1. Using the 2019 financial statement information for Johnson and Johnson (JNJ) combined with the Valueline survery, score Johnson and Johnson (JNJ) based on the 10 original screening criteria. (Make a spreadsheet) 2. Would JNJ make it to the second round? Why or why not? 3. Now assume JNJ passes the initial round. Would it be considered a buy after going through the second round? Why or why not? 4. What was the criteria for the Rea-Graham fund? | 5. Now look at JNJ based on the new reduced criteria. Would JNJ be included as a candidate for investment? Why or why not? 30 Pent LAR 156 1430 85 wted *** 723 122 M SA its work on finding headlines for lyst at the bottom of the share-earings may RECENT PE Train: 16 RELATIVE DIVD LINE TIMELINESS 1 2130 High: 65.4 102 681 72.7 90.0 10.5 106.5 120.1 144.4 143.0 1478 157.0 LOW 569 57.5 61.7 70.3 30.1 Target Price Range 34.3 110.3 113.6 125.0 100.2 SAFETY 1 1970 2023 2024 2025 LEGENDS TECHNICAL 2 54530 130 Cash Flows .. were 00 Oplan BETA 100 Mulut -200 18-Month Target Price Range 160 Low High Midpoints to Md -138 $127-6100 2023-35 PROJECTIONS .60 Anni Total Price Raftur Moh 230 145 14305 Institutional Decisions STOT. RETURN 420 200000 Bu 1114 1101 d 1325 1431 1272 20 1913 WIB minimum 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 ILLELNE PUB LLC 23-8 15. 169 18.43 2151 23.02 24 24.19 520 5.44 2650 280 3117 21.20 31.10 Spesh 460 5.23 522 549 5.C 6:48 7.00 6.36 750 764 B35 1152 11.85 Cash Flower 890 350 39 4.15 49 4.13 45 5.00 5.10 5.52 5.70 548 593 541 561 86 7:50 9.90 Earnings per 1.10 123 11.48 1.80 1.13 2.11 235 2.40 2.50 2.78 2.35 315 354 275 2.95 US Div Dec per 5.50 .73 104 UT 136 120 1.19 150 capSpording persh 150 10.71 12.73 13.50 15.25 1535 18:37 21.66 20:36 23:33 25 25 25.00 35 28.02 224 225 25.00 21.5 Book Value per 41.20 2110 22204022/0922143273412724422.20.0 212 230 2700 2.2222232200 2008 Commonsi 21 185 760 75.4 143 125 127 156 17.7 181 156 Boere Ang A'I PER 120 10 0 30 92 100 120 120 N he Relative PE Ratio 20% 205 23% 25% 285 99% 3.4% 356 3.05 2.0 2.7% 30 2.2% 2.6 27 235 Ang And Yield CAPITAL STRUCTURE M of 920 61587 55030 6724 71312 78331 7007471890 75456 81581 1205008000 Sales Sil 10400 Total Debt $27.583 mil. Due in Syrs $0.2 mil. LT Debt 925.393 ml LT interest S100 ml 31.432.35 35.5 33.9% 237 21.15 e 21.7% 23.158.3% 41:55 13:05 Operating Margin SS 2009031580 36D 4540303037140 56420 692070093 7000 7280 Depreciation Smil 000 1999 137 1434515825 182731540918540 SABE 15237 23:10 20000 29500 Net Profit Sil 30000 Lesses, Un capitalized Annual rentals $215 mil 2015 2015 2 1 2 137 35% 1578 150 17% 16.05 1755 Income Tax Rate 11:38 215 21:35 2136 22.9% 220 22.0% 200% 19.4% 18.2.45 MS17 Mel Proft Mergin 2. Pension Assets-12/195322 Oblig. $372 bill 24235 356 210854 372 3226 3299 300 3351 140 000 17500 27500 Wateng Caplnil Preferred Stock None 91560 12800 11489 1389 15122 12857 22442 30675 27684 5494 25000 24000 Long Term Debt 740530072711502411001001 1080p Commen Stock 2.004.104.55 shares 2064 20241919 18.8% 1815 273% 2235 2405 Return on Total Cap 2. as of 42220 23525 2215 21.4% 234 21.7% 224.7%252520.00 1155 Return on Sr. Equity MARKET CAP: 5391 bilion Large Cap 1326 13.5% 1196 11% 1234 10.2012 9.3% 9.71 2255 1695 Retained to com 15.05 CURRENT POSITION 2016 2019 20 441 45 59% 524 SILI 0 Al Disto Metro Cash Asus 19587 19287 Receves 1400 14481 18024 BUSINESS: Jchraon & Johnson is engaged in the research forthopedic surgery, ventional solutions, and a health Inventory (FIFO) 8529 9020 14574 wlanet, manufacture and sale of a broad range of products in Employs approximately 150.200. Officers & directors than Other us the healthcare Sold. perates the business segments com os common stock Vargard Group, 1. Black Pack 7.3 Current Assets 48083 76274 metabycare, beauty, skin care, oral care, wound care, c.). State Street. 3/20 Pro Chaman & CEO: Alex Gorsky Ata Payable 7537 44 7411 Pharmaceutical Cartinet antion that contraceptive Inc. Address: One Johnson & Johnson Plaza, New Brunswick Debt Dud 2190 dermatology, gastrointestinal ). and Medical Devon N33. Telephone: 732-624-0400. Intumet www.com Other 2408 Current Lab a Johnson & Johnson shares have come successful development of a drug is not a ANNUAL RATES Past Past Este 179 being hard hit by initial fears over the reputable and well-funded outfit seeking roaring back in recent weeks after certainty. Too, there are many other of charge per 10 Sales 20% 3.55 5.0% "Cash Flow 5.0% 55% 8.5% the end, they are trading in the same vi vided guidance during its first quarter Caming 40% 19.05 Dividers 7.0% 7.55 Book Value 25% ary review, just shy of their all-time price cited about. It said that it expects earnings apex. While the company's better than andar Mer Per Sun Pur Sap Per Dec. Per to expected first quarter Sorul were en hare, down from its previous $8.95 $9.10 2014 2000 2001 2318 3 1581 recent momentum seems to being fueled calls for an 11% decline. The top line 2019 20001 2082 20729 2017 about se bathedreasing optimism 2020 20001 17000 TR250 20550 76500 hes the is pegged to fall 2.0%-5.5%, and margins conglomerate's consumer goods are expected to be pinched by investments 2021 21000 21500 21500 22000 18000 and pharmaceuticals to help combat the pandemic. We current- The EARNINGS PER SHARE O Cal company is a endar Mar Per Jun. Per Sep. Per Dec.Per 2017 It entered into a joint col 161 $1 billion 140 137 1.00 be too optimistie with its 2018 1.50 1.45 1.12 laboration with the Biomedical Advanced sumption market stabilization in the 2019 2.10 2.58 2.12 1.82 Research and Development Association third quarter. 2020 230 1.50 1.80 1.90 150 BARDA) to help find, develop, and manu- These shares are ranked 1 Highest) 2021 2.30 235 2.20 2.15 9.00 facture one billion doses of a vaccine for Timeliness. That said, those looking QUARTERLY DIDEOS PAD Leadership said that it has identified a further out will want to be cautious here, endar Mat 31 30 Sep 20 Dec 31 Prod lead candidate to treat the disease, and as the recent price strength discounts a that it could be ready for emergency-use good share of the gains we see out to 2023 2016 75 B. 80 .80 3.15 authorization in 2017 80 .BA 84 2025. Prospects are better on risk early 2021. .84 2018 84 90 90 The near-term operating environment adjusted basis, but JNJ is also facing stiff 2019 90 .96 95 .95 3. presents aheadwind, nonetheless, headwinds on the litigation front 20120 1.01 While the BARDA agreement is a positive, Andre J. Costanza May 15, 20:20 A) Years and on the last Sunday in December 0716 4 117,055.73 ide to tax reform): September and December - Dividendron Company's Financial Strength Dited earrings Excludes normering 10 $3.05) 20. (136) GAAP tom 2015-2018 ment plan available Stock Price Stability 900 04, 205, 206, Casero Next caninos por due muy ID includes intangibles. On 12/31/18 513 dzic 10, 211, 51.51; 12.0512413, Price Growth Persistence (C) Dividers Historically paid: March, Jure blon, 530.5 a share. (E) in milions Earnings Predictability DE PASS NOT RESPOASBLE FOR ANY ERRORS OR OMISSIONS PEPER.Thaptentry for the below for team. We per To subscribe call 1-800-VALUELINE as a um, Year cine. It agement 85 70 In addition to your spreadsheet, you will need to provide answers to the following questions: 1. Using the 2019 financial statement information for Johnson and Johnson (JNJ) combined with the Valueline survery, score Johnson and Johnson (JNJ) based on the 10 original screening criteria. (Make a spreadsheet) 2. Would JNJ make it to the second round? Why or why not? 3. Now assume JNJ passes the initial round. Would it be considered a buy after going through the second round? Why or why not? 4. What was the criteria for the Rea-Graham fund? | 5. Now look at JNJ based on the new reduced criteria. Would JNJ be included as a candidate for investment? Why or why not? 30 Pent LAR 156 1430 85 wted *** 723 122 M SA its work on finding headlines for lyst at the bottom of the share-earings may RECENT PE Train: 16 RELATIVE DIVD LINE TIMELINESS 1 2130 High: 65.4 102 681 72.7 90.0 10.5 106.5 120.1 144.4 143.0 1478 157.0 LOW 569 57.5 61.7 70.3 30.1 Target Price Range 34.3 110.3 113.6 125.0 100.2 SAFETY 1 1970 2023 2024 2025 LEGENDS TECHNICAL 2 54530 130 Cash Flows .. were 00 Oplan BETA 100 Mulut -200 18-Month Target Price Range 160 Low High Midpoints to Md -138 $127-6100 2023-35 PROJECTIONS .60 Anni Total Price Raftur Moh 230 145 14305 Institutional Decisions STOT. RETURN 420 200000 Bu 1114 1101 d 1325 1431 1272 20 1913 WIB minimum 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 ILLELNE PUB LLC 23-8 15. 169 18.43 2151 23.02 24 24.19 520 5.44 2650 280 3117 21.20 31.10 Spesh 460 5.23 522 549 5.C 6:48 7.00 6.36 750 764 B35 1152 11.85 Cash Flower 890 350 39 4.15 49 4.13 45 5.00 5.10 5.52 5.70 548 593 541 561 86 7:50 9.90 Earnings per 1.10 123 11.48 1.80 1.13 2.11 235 2.40 2.50 2.78 2.35 315 354 275 2.95 US Div Dec per 5.50 .73 104 UT 136 120 1.19 150 capSpording persh 150 10.71 12.73 13.50 15.25 1535 18:37 21.66 20:36 23:33 25 25 25.00 35 28.02 224 225 25.00 21.5 Book Value per 41.20 2110 22204022/0922143273412724422.20.0 212 230 2700 2.2222232200 2008 Commonsi 21 185 760 75.4 143 125 127 156 17.7 181 156 Boere Ang A'I PER 120 10 0 30 92 100 120 120 N he Relative PE Ratio 20% 205 23% 25% 285 99% 3.4% 356 3.05 2.0 2.7% 30 2.2% 2.6 27 235 Ang And Yield CAPITAL STRUCTURE M of 920 61587 55030 6724 71312 78331 7007471890 75456 81581 1205008000 Sales Sil 10400 Total Debt $27.583 mil. Due in Syrs $0.2 mil. LT Debt 925.393 ml LT interest S100 ml 31.432.35 35.5 33.9% 237 21.15 e 21.7% 23.158.3% 41:55 13:05 Operating Margin SS 2009031580 36D 4540303037140 56420 692070093 7000 7280 Depreciation Smil 000 1999 137 1434515825 182731540918540 SABE 15237 23:10 20000 29500 Net Profit Sil 30000 Lesses, Un capitalized Annual rentals $215 mil 2015 2015 2 1 2 137 35% 1578 150 17% 16.05 1755 Income Tax Rate 11:38 215 21:35 2136 22.9% 220 22.0% 200% 19.4% 18.2.45 MS17 Mel Proft Mergin 2. Pension Assets-12/195322 Oblig. $372 bill 24235 356 210854 372 3226 3299 300 3351 140 000 17500 27500 Wateng Caplnil Preferred Stock None 91560 12800 11489 1389 15122 12857 22442 30675 27684 5494 25000 24000 Long Term Debt 740530072711502411001001 1080p Commen Stock 2.004.104.55 shares 2064 20241919 18.8% 1815 273% 2235 2405 Return on Total Cap 2. as of 42220 23525 2215 21.4% 234 21.7% 224.7%252520.00 1155 Return on Sr. Equity MARKET CAP: 5391 bilion Large Cap 1326 13.5% 1196 11% 1234 10.2012 9.3% 9.71 2255 1695 Retained to com 15.05 CURRENT POSITION 2016 2019 20 441 45 59% 524 SILI 0 Al Disto Metro Cash Asus 19587 19287 Receves 1400 14481 18024 BUSINESS: Jchraon & Johnson is engaged in the research forthopedic surgery, ventional solutions, and a health Inventory (FIFO) 8529 9020 14574 wlanet, manufacture and sale of a broad range of products in Employs approximately 150.200. Officers & directors than Other us the healthcare Sold. perates the business segments com os common stock Vargard Group, 1. Black Pack 7.3 Current Assets 48083 76274 metabycare, beauty, skin care, oral care, wound care, c.). State Street. 3/20 Pro Chaman & CEO: Alex Gorsky Ata Payable 7537 44 7411 Pharmaceutical Cartinet antion that contraceptive Inc. Address: One Johnson & Johnson Plaza, New Brunswick Debt Dud 2190 dermatology, gastrointestinal ). and Medical Devon N33. Telephone: 732-624-0400. Intumet www.com Other 2408 Current Lab a Johnson & Johnson shares have come successful development of a drug is not a ANNUAL RATES Past Past Este 179 being hard hit by initial fears over the reputable and well-funded outfit seeking roaring back in recent weeks after certainty. Too, there are many other of charge per 10 Sales 20% 3.55 5.0% "Cash Flow 5.0% 55% 8.5% the end, they are trading in the same vi vided guidance during its first quarter Caming 40% 19.05 Dividers 7.0% 7.55 Book Value 25% ary review, just shy of their all-time price cited about. It said that it expects earnings apex. While the company's better than andar Mer Per Sun Pur Sap Per Dec. Per to expected first quarter Sorul were en hare, down from its previous $8.95 $9.10 2014 2000 2001 2318 3 1581 recent momentum seems to being fueled calls for an 11% decline. The top line 2019 20001 2082 20729 2017 about se bathedreasing optimism 2020 20001 17000 TR250 20550 76500 hes the is pegged to fall 2.0%-5.5%, and margins conglomerate's consumer goods are expected to be pinched by investments 2021 21000 21500 21500 22000 18000 and pharmaceuticals to help combat the pandemic. We current- The EARNINGS PER SHARE O Cal company is a endar Mar Per Jun. Per Sep. Per Dec.Per 2017 It entered into a joint col 161 $1 billion 140 137 1.00 be too optimistie with its 2018 1.50 1.45 1.12 laboration with the Biomedical Advanced sumption market stabilization in the 2019 2.10 2.58 2.12 1.82 Research and Development Association third quarter. 2020 230 1.50 1.80 1.90 150 BARDA) to help find, develop, and manu- These shares are ranked 1 Highest) 2021 2.30 235 2.20 2.15 9.00 facture one billion doses of a vaccine for Timeliness. That said, those looking QUARTERLY DIDEOS PAD Leadership said that it has identified a further out will want to be cautious here, endar Mat 31 30 Sep 20 Dec 31 Prod lead candidate to treat the disease, and as the recent price strength discounts a that it could be ready for emergency-use good share of the gains we see out to 2023 2016 75 B. 80 .80 3.15 authorization in 2017 80 .BA 84 2025. Prospects are better on risk early 2021. .84 2018 84 90 90 The near-term operating environment adjusted basis, but JNJ is also facing stiff 2019 90 .96 95 .95 3. presents aheadwind, nonetheless, headwinds on the litigation front 20120 1.01 While the BARDA agreement is a positive, Andre J. Costanza May 15, 20:20 A) Years and on the last Sunday in December 0716 4 117,055.73 ide to tax reform): September and December - Dividendron Company's Financial Strength Dited earrings Excludes normering 10 $3.05) 20. (136) GAAP tom 2015-2018 ment plan available Stock Price Stability 900 04, 205, 206, Casero Next caninos por due muy ID includes intangibles. On 12/31/18 513 dzic 10, 211, 51.51; 12.0512413, Price Growth Persistence (C) Dividers Historically paid: March, Jure blon, 530.5 a share. (E) in milions Earnings Predictability DE PASS NOT RESPOASBLE FOR ANY ERRORS OR OMISSIONS PEPER.Thaptentry for the below for team. We per To subscribe call 1-800-VALUELINE as a um, Year cine. It agement 85 70